{"id":1011260,"date":"2026-10-19T08:43:52","date_gmt":"2026-10-19T12:43:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/"},"modified":"2026-10-19T08:43:52","modified_gmt":"2026-10-19T12:43:52","slug":"diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/","title":{"rendered":"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl1 { padding-left: 5px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwwidth100 { width: 100% }\n.bwwidth15 { width: 15% }\n.bwwidth85 { width: 85% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026<\/i><\/b><\/li>\n<li><b><i>Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts<\/i><\/b><\/li>\n<\/ul>\n<p>MINNEAPOLIS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held on<b \/>Tuesday, November 24, 2026, at 8:00am Eastern Time.<\/p>\n<p>\nThe new date will allow the Company to expand the presentation to include preliminary, interim topline results from the second cohort of the investigator-sponsored Phase 2 early-onset FGR trial, in addition to results from the first cohort. The event will cover FGR and the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment for FGR.<\/p>\n<p><b>Webinar Panel and Event Details<\/b><\/p>\n<p>\nThe webinar will feature Professor Catherine Cluver, MD, PhD (Stellenbosch University), Professor Stephen Tong, MBBS, PhD (The University of Melbourne), Professor Susan Walker, AO, MBBS, MD (The University of Melbourne), and Professor Andrew Shennan, OBE, MBBS, MD (King\u2019s College London). The experts will discuss the FGR disease state and current treatment landscape, the role of placental insufficiency and impaired uteroplacental blood flow, the clinical rationale for DM199 as a potential treatment option for FGR, and interim safety and clinical findings from the first six participants treated in the Phase 2 early-onset FGR trial.<\/p>\n<p>\nDr. Cluver, the trial Principal Investigator, will review the trial design and present safety, tolerability and preliminary first and second cohort results. The panel will discuss the clinical relevance of key measures being evaluated in the trial, and the interim findings in the context of early-onset FGR.<\/p>\n<p>\nA live question-and-answer session will follow the formal presentations.<\/p>\n<p><b>Event Details<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwwidth15 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Date<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwwidth85 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTuesday, November 24, 2026<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwwidth15 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Time<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwwidth85 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n8:00 AM EST \/ 7:00 AM CST<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwwidth15 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Registration<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwwidth85 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fus-west-2.protection.sophos.com%3Fd%3Dlifescievents.com%26u%3DaHR0cHM6Ly9saWZlc2NpZXZlbnRzLmNvbS9ldmVudC9kanY1dThwLw%3D%3D%26i%3DNjU1NmE0NWY4MzA0ZjA2ZTMwNTBjNWRl%26t%3DZ3JMQlZrd0dCazNQSDF5WS9rZVB3Q1E3UnRCNzVRSnMxM3l1b0F0WVhDOD0%3D%26h%3D00998f842cd2420ba822cdb508dc422c%26s%3DAVNPUEhUT0NFTkNSWVBUSVaRM1ge1KdCu6XuHsD7eVM6ajf8zGdShM8230xmydilvbg1fgWBPIq6cOTm4Ra6jDU&amp;esheet=54624268&amp;newsitemid=20261019862168&amp;lan=en-US&amp;anchor=https%3A%2F%2Flifescievents.com%2Fevent%2Fdjv5u8p%2F&amp;index=1&amp;md5=87411761cf63d9a7a83a9f1bd97dc5af\">https:\/\/lifescievents.com\/event\/djv5u8p\/<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>About Professor Catherine Cluver<\/b><\/p>\n<p>\nProfessor Catherine Cluver is a maternal-fetal medicine specialist who founded and leads the Preeclampsia Research Unit at Tygerberg Hospital, Stellenbosch University, South Africa. Dr. Cluver has completed multiple preeclampsia treatment trials assessing novel therapies and curates one of the largest preeclampsia biobanks. She has published extensively in maternal-fetal medicine, including work in The Lancet and BMJ. Dr. Cluver is the Principal Investigator of the ongoing investigator-sponsored Phase 2 trial evaluating DM199 in preeclampsia and fetal growth restriction at Tygerberg Hospital.<\/p>\n<p><b>About Professor Stephen Tong<\/b><\/p>\n<p>\nProfessor Stephen Tong is an obstetrician-scientist at the University of Melbourne and Mercy Hospital for Women with a strong focus on translational research and the development of therapeutics for major pregnancy complications. He has played a leading role in advancing multiple therapeutic concepts from laboratory research into Phase 1 through Phase 3 clinical trials. Professor Tong has authored more than 300 scientific publications, including more than 100 on preeclampsia, with research published in journals including Nature, The Lancet, BMJ and Nature Communications.<\/p>\n<p><b>About Professor Susan Walker<\/b><\/p>\n<p>\nProfessor Susan Walker is the Sheila Handbury Chair of Maternal Fetal Medicine, Head of the Department of Obstetrics, Gynaecology and Newborn Health at the University of Melbourne, and Divisional Chair of Perinatal Medicine at Mercy Hospital for Women. Her clinical and research program focuses on improving the detection and treatment of fetal growth restriction and preeclampsia. Professor Walker has authored more than 290 publications, including work in The Lancet, New England Journal of Medicine and BMJ.<\/p>\n<p><b>About Professor Andrew Shennan<\/b><\/p>\n<p>\nAndrew Shennan is Professor of Obstetrics at King\u2019s College London, based at St. Thomas\u2019 Hospital and specializes in clinical trials and the management of high-risk pregnancy. His research focuses on the prediction and prevention of preterm birth and preeclampsia, as well as reducing maternal and perinatal mortality. Professor Shennan has published more than 700 peer-reviewed research reports and has held leadership roles including Chair of the FIGO Preterm Birth Committee and Chair of Action on Pre-eclampsia UK. He also maintains an active clinical practice, including management of high-risk obstetric patients and a specialist preterm birth surveillance clinic.<\/p>\n<p><b>About the Phase 2 Investigator-Sponsored Fetal Growth Restriction Trial<\/b><\/p>\n<p>\nThe Phase 2 study is the third part of an open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored trial of DM199 for the treatment of pregnancy complications currently being conducted at the Tygerberg Hospital in Cape Town, South Africa.<\/p>\n<p>\nThis part of the trial is evaluating repeated SC dosing in up to 30 early-onset FGR subjects until delivery, using up to three dose levels initially based on Part 1a data; enrollment commenced in June 2026, and the first two cohorts of 12 participants has been enrolled. Dosing levels are at 5, 10 and up to 15 \u00b5g\/kg. The dose for the third cohort will be between 1 and 15 \u00b5g\/kg based on results from the first two cohorts.<\/p>\n<p><b>About Fetal Growth Restriction<\/b><\/p>\n<p>\nFetal growth restriction (FGR) occurs when a fetus fails to reach its genetically determined growth potential in the womb, most commonly due to placental insufficiency. FGR affects an estimated 10% of pregnancies worldwide and is associated with significantly increased risks of stillbirth, preterm birth, and neonatal morbidity, as well as long-term neurodevelopmental, cardiovascular, and metabolic complications. In severe, early-onset cases, FGR often necessitates delivery before 32 weeks of gestation, when the risks of prematurity must be weighed against the dangers of continued growth restriction in utero. For further details, see the recently released white paper, \u201c<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_314e13f77f338be29b6247ea6148518d%2Fdiamedica%2Fdb%2F283%2F3342%2Fdescription%2FThe_Potential_of_DM199_to_Treat_Fetal_Growth_Restriction_-_Sept_2026.pdf&amp;esheet=54624268&amp;newsitemid=20261019862168&amp;lan=en-US&amp;anchor=The+Potential+of+DM199+to+Treat+Fetal+Growth+Restriction&amp;index=2&amp;md5=e1e112ec7ade60dc9de58033229bb6ce\"><i>The Potential of DM199 to Treat Fetal Growth Restriction<\/i><\/a><i>\u201d.<\/i><\/p>\n<p><b>About DM199 (rinvecalinase alfa)<\/b><\/p>\n<p>\nDM199 is a recombinant form of human tissue kallikrein-1 (rhKLK1). KLK1 is a serine protease enzyme that plays an important role in in vascular regulation through the kallikrein-kinin system, activating downstream pathways that increase the production and release of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor.<\/p>\n<p><b>About DiaMedica Therapeutics Inc.<\/b><\/p>\n<p>\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica\u2019s lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.diamedica.com&amp;esheet=54624268&amp;newsitemid=20261019862168&amp;lan=en-US&amp;anchor=www.diamedica.com&amp;index=3&amp;md5=961bc92b0cc02f924df1dce71605bc61\">www.diamedica.com<\/a>.<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management\u2019s current expectations. When used in this press release, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould,\u201d the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the timing and key opinion leader participation of the upcoming webinar on DM199 for fetal growth restriction. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the timing and outcomes of non-clinical studies; risks and uncertainties relating to the timing of studies and trials;; and the risks identified under the heading \u201cRisk Factors\u201d in DiaMedica\u2019s annual report on Form 10-K for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports, including our most recent quarterly report on Form 10-Q. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261019862168\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261019862168\/en\/<\/a><\/span><\/p>\n<p><b>Scott Kellen<br \/>\n<\/b><br \/>Chief Financial Officer<br \/>\n<br \/>Phone: (763) 496-5118<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:skellen@diamedica.com\">skellen@diamedica.com<\/a><\/p>\n<p><b>For Investor Inquiries:<br \/>\n<\/b><br \/>Mike Moyer<br \/>\n<br \/>Managing Director, LifeSci Advisors, LLC<br \/>\n<br \/>Phone: (617) 308-4306<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mmoyer@lifesciadvisors.com\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Madelin Hawtin<br \/>\n<br \/>LifeSci Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mhawtin@lifescicomms.com\">mhawtin@lifescicomms.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Minnesota Africa United States South Africa North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research FDA Clinical Trials Cardiology Biotechnology Health Pharmaceutical Other Science Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261019862168\/en\/2816437\/3\/DiaMedica-Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026 Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held onTuesday, November 24, 2026, at 8:00am Eastern Time. The new date will allow the Company to expand the presentation to include preliminary, interim topline results from the second cohort of the investigator-sponsored Phase &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011260","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026 Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held onTuesday, November 24, 2026, at 8:00am Eastern Time. The new date will allow the Company to expand the presentation to include preliminary, interim topline results from the second cohort of the investigator-sponsored Phase &hellip; Continue reading &quot;DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-19T12:43:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar\",\"datePublished\":\"2026-10-19T12:43:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/\"},\"wordCount\":1424,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/\",\"name\":\"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-19T12:43:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/","og_locale":"en_US","og_type":"article","og_title":"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - Market Newsdesk","og_description":"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026 Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held onTuesday, November 24, 2026, at 8:00am Eastern Time. The new date will allow the Company to expand the presentation to include preliminary, interim topline results from the second cohort of the investigator-sponsored Phase &hellip; Continue reading \"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-19T12:43:52+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar","datePublished":"2026-10-19T12:43:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/"},"wordCount":1424,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/","name":"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-19T12:43:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261019862168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-provides-update-on-fetal-growth-restriction-key-opinion-leader-webinar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011260"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011260\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}